Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.